Getein Biotech

Getein Biotech FCF/Debt

The Free Cash Flow to Debt Ratio of Getein Biotech (603387.SS) as of Oct 15, 2026 is 46.19 %. In the previous year, Free Cash Flow to Debt Ratio was 11.66 % — a change of 296.11% (higher).

FCF/Debt

46.19 %

YoY

296.11%

Last updated:

Free Cash Flow to Debt Ratio of Getein Biotech is 2024 46.19 % . Free Cash Flow to Debt Ratio of Getein Biotech was 2023 11.66 % . It decreases by 296.11% higher compared to the previous year.

The Getein Biotech FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
244.43 CNY
Jan 1, 2019
106.23 CNY
Jan 1, 2020
18.69 CNY
Jan 1, 2021
50.91 CNY
Jan 1, 2022
44.92 CNY
Jan 1, 2023
11.66 CNY
Jan 1, 2024
46.19 CNY
The Getein Biotech FCF/Debt history
YEARFCF/DebtYoY
46.19 %+296.11%
11.66 %-74.04%
44.92 %-11.76%
50.91 %+172.34%
18.69 %-82.40%
106.23 %-56.54%
244.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc, listed on the Shanghai Stock Exchange under ticker 603387.SS, is a biotechnology company headquartered in Nanjing, China. The company went public on July 17, 2017, and currently employs 2,508 full-time staff. Its primary business focuses on the medical health industry chain, with operations centered around in vitro diagnostic reagents and related instruments. The company produces a range of diagnostic reagents, including Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. It also develops diagnostic instruments such as the immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000, and the five classification blood cell analyzer BHA-5000. In addition to manufacturing, Getein Biotech offers testing and agency services. Its products are distributed both domestically within China and internationally. The company maintains a website at www.getein.com.cn for further information. As a biotechnology firm operating in the healthcare sector, Getein Biotech Inc is positioned within the broader health care industry, contributing to diagnostic solutions for medical professionals and institutions. The company's focus on in vitro diagnostics aligns with its role in supporting healthcare systems through advanced testing technologies and equipment. Getein Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Getein Biotech stock

Free Cash Flow to Debt Ratio of Getein Biotech is 46.19 % in 2024.

Free Cash Flow to Debt Ratio of Getein Biotech changed from 11.66 % to 46.19 %, representing a 296.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Getein Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Getein Biotech

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Getein Biotech